Skip to content
10-Q

Quarterly Report

Dicerna Pharmaceuticals Inc

0001399529-21-000089

← back to feed
Filed
May 6, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2021 · Apr 30, 2021 76.9M sh
Shares Diluted Q1 2021 · Mar 31, 2021 76.26M sh
Shares Diluted Q1 2021 · Mar 31, 2020 72.92M sh
Capex Q1 2021 · Mar 31, 2021 $3.38M
Capex Q1 2021 · Mar 31, 2020 $1.38M
Operating Cash Flow Q1 2021 · Mar 31, 2021 −$26.7M
Operating Cash Flow Q1 2021 · Mar 31, 2020 $321.08M
Cash And Equivalents Q1 2021 · Mar 31, 2021 $159.11M
Cash And Equivalents Q1 2021 · Dec 31, 2020 $126.02M
Cash And Equivalents Q1 2021 · Mar 31, 2020 $245.48M
Stockholders Equity Q1 2021 · Mar 31, 2021 $126.4M
Stockholders Equity Q1 2021 · Dec 31, 2020 $137.75M
Stockholders Equity Q1 2021 · Mar 31, 2020 $177.91M
Stockholders Equity Q1 2021 · Dec 31, 2019 $152.2M
Current Liabilities Q1 2021 · Mar 31, 2021 $182.15M
Current Liabilities Q1 2021 · Dec 31, 2020 $177.94M
Total Liabilities Q1 2021 · Mar 31, 2021 $557.01M
Total Liabilities Q1 2021 · Dec 31, 2020 $570.09M
Current Assets Q1 2021 · Mar 31, 2021 $594.5M
Current Assets Q1 2021 · Dec 31, 2020 $618.7M
Total Assets Q1 2021 · Mar 31, 2021 $683.41M
Total Assets Q1 2021 · Dec 31, 2020 $707.85M
Eps Diluted Q1 2021 · Mar 31, 2021 −$0.39
Eps Diluted Q1 2021 · Mar 31, 2020 −$0.31
Eps Basic Q1 2021 · Mar 31, 2021 −$0.39
Eps Basic Q1 2021 · Mar 31, 2020 −$0.31
Sga Expense Q1 2021 · Mar 31, 2021 $20.67M
Sga Expense Q1 2021 · Mar 31, 2020 $16.02M
Rd Expense Q1 2021 · Mar 31, 2021 $56.04M
Rd Expense Q1 2021 · Mar 31, 2020 $43.17M
Net Income Q1 2021 · Mar 31, 2021 −$29.97M
Net Income Q1 2021 · Mar 31, 2020 −$22.49M
Operating Income Q1 2021 · Mar 31, 2021 −$29.11M
Operating Income Q1 2021 · Mar 31, 2020 −$25.17M
Revenue Q1 2021 · Mar 31, 2021 $47.6M
Revenue Q1 2021 · Mar 31, 2020 $34.03M